[ad_1]
ANI Pharmaceuticals, Inc. (“ANI” or “Company”) (NASDAQ:State Intellectual Property Office) Announced today that the company has resubmitted Cortrophin’s Supplemental New Drug Application (“sNDA”)® Gel and the U.S. Food and Drug Administration (“FDA”).
“We are very pleased to resubmit the sNDA of Cortrophin Gel in the last week of June. ANI carefully reviewed every communication between the FDA and our internal subject matter experts and obtained additional expert advice from industry consultants to make every effort to resolve All FDA comments. Cortrophin Gel is an important product of ANI. We look forward to bringing this product to the market. If approved, it can benefit patients. I sincerely thank the ANI team and our partners for their hard work and dedication support to reapply,” Said Nikhil Lalwani, CEO of ANI Pharmaceuticals.
About ANI
ANI Pharmaceuticals, Inc. is a comprehensive professional pharmaceutical company focusing on…
The full story on Benzinga.com
[ad_2]
Source link
